Alkem Laboratories Limited
All news and filings related to Alkem Laboratories Limited.
View all news & filings- Medium impact
Alkem Labs launches India's first patented Ginsenoside Exosome hair growth serum, Renocia Exo™
Alkem Laboratories launched Renocia Exo™, India's first patented Ginsenoside Exosome-based hair growth serum. The therapy supports hair follicle health and vitality using phyto-exosomes, peptides, and actives. Managing Director Sandeep Singh highlighted its multi-targeted approach to hair loss management.
Read the summary - Medium impact
Alkem Laboratories 52nd AGM: All resolutions passed with significant majority
Alkem Laboratories' 52nd AGM on August 27, 2026, saw all resolutions passed. Key approvals include financial statements for FY26, dividend declaration, and re-appointments of directors Sandeep Singh, Sarvesh Singh, and Mrs. Madhurima Singh.
Read the summary - Medium impact
Alkem Labs Q1 FY27 Call Transcript Released: Revenue Up 11% to ₹3,740 Cr
Alkem Laboratories reported Q1 FY27 revenue of ₹3,740 Cr, up 11% YoY. India sales grew 10.3% to ₹2,497 Cr, and international sales rose 16% to ₹1,222 Cr. EBITDA margin stood at 20.5%. Net profit declined 21.7% due to taxation. The company outperformed the Indian pharmaceutical market.
Read the summary - High impact
Alkem Labs Shareholders Approve Amalgamation Scheme with Adroit Biomed
Alkem Laboratories Limited shareholders approved the amalgamation scheme with Adroit Biomed Limited. The resolution passed with 99.9999% of votes in favor during a meeting held on August 17, 2026. The NCLT-ordered meeting confirmed strong shareholder backing for the corporate action.
Read the summary - Medium impact
Alkem Labs Q1FY27 Results: Total Income ₹3,740 Crore, Net Profit ₹520 Crore
Alkem Laboratories reported Q1FY27 results. Total income was ₹3,740 crore, and net profit was ₹520 crore. Comprehensive income was ₹523 crore. Basic and diluted EPS stood at ₹43.49. The results were approved by the Board on August 14, 2026.
Read the summary - Low impact
Alkem Labs Q1FY27 Earnings Conference Call Audio Recording Available
Alkem Laboratories Limited announced the availability of the audio recording for its Q1FY27 Earnings Conference Call. The recording can be accessed on the company's website at https://www.alkemlabs.com/investors/earnings-call.
Read the summary - Low impact
Alkem Laboratories: Trading Window Reopens August 17th Post Q1FY27 Results
Alkem Laboratories' trading window will reopen on August 17th, 2026. This decision follows the disclosure of the company's financial results for the quarter ended June 30th, 2026, on August 14th, 2026.
Read the summary - Medium impact
Alkem Labs Approves ₹75 Crore Investment for New Manufacturing Facility in Baddi
Alkem Laboratories' Board has approved setting up a new manufacturing block at its Baddi facility. The company will invest up to ₹75 crores for this expansion, aiming to boost its production capacity.
Read the summary - Medium impact
Alkem Labs Q1FY27 Revenue Up 10.9% to ₹37,402 Crore
Alkem Laboratories reported Q1FY27 revenue of ₹37,402 crore, up 10.9% YoY. India sales grew 10.3% to ₹24,978 crore, while international sales increased 16.0% to ₹12,223 crore. EBITDA rose 3.7% to ₹7,661 crore. Net profit declined 21.7% to ₹5,200 crore.
Read the summary - Medium impact
Alkem Labs Q1 FY27 Consolidated Revenue at ₹3,740 Crore, Profit at ₹521 Crore
Alkem Laboratories reported consolidated revenue of ₹3,740.15 crore and profit after tax of ₹519.96 crore for Q1 FY27. Standalone revenue was ₹2,667.73 crore with profit after tax of ₹569.98 crore. The results were approved by the board on August 14, 2026.
Read the summary - Medium impact
Alkem Labs' Daman Facility FDA Inspection Classified OAI
Alkem Laboratories' Daman manufacturing facility's US FDA inspection has been classified as Official Action Indicated (OAI). The company received seven observations during the April 20-May 1, 2026 inspection. Alkem continues to supply products from the facility to the US market and is working towards full compliance.
Read the summary - Low impact
Alkem Laboratories Appoints Mr. Rajpal Singh Rana as Senior Management Personnel
Alkem Laboratories appointed Mr. Rajpal Singh Rana as Senior Management Personnel, effective August 3rd, 2026. Mr. Rana has over 30 years of experience in pharmaceutical marketing and sales. He holds an MBA in Marketing and a B.Sc.
Read the summary - Low impact
Alkem Labs Dispatches AGM Notice & Annual Report, Announces E-voting Facility
Alkem Laboratories has dispatched its 52nd AGM notice and Annual Report for FY 2025-26. The AGM will be held on August 27, 2026, via video conference. Shareholders can e-vote from August 24-26, 2026. The cut-off date for voting rights is August 20, 2026.
Read the summary - Low impact
Alkem Labs to host Q1FY27 earnings call on Aug 14
Alkem Laboratories will hold a conference call on August 14, 2026, at 4:30 PM IST to discuss its Q1FY27 financial results. The call will feature MD Sandeep Singh and CFO Nitin Agrawal. Motilal Oswal Securities will host the event.
Read the summary - Low impact
Alkem Labs Senior Management Personnel Dr. Jitendra Singh Huda Resigns
Dr. Jitendra Singh Huda, Senior Management Personnel at Alkem Laboratories Limited, has resigned. His resignation is effective July 23, 2026. The company acknowledged his contributions. Dr. Huda cited professional growth as the reason for his departure.
Read the summary - Medium impact
Alkem Labs completes acquisition of Occlutech Holding AG
Alkem Laboratories Limited has completed the acquisition of Occlutech Holding AG, a Swiss company. Its subsidiary, Alkem Medtech, acquired between 51% and 55% of Occlutech's equity share capital. Occlutech will now be a step-down subsidiary of Alkem.
Read the summary - Medium impact
Alkem Laboratories Shareholders Meeting on Aug 17 for Amalgamation Scheme
Alkem Laboratories will hold an equity shareholder meeting on August 17, 2026, via video conference to approve the amalgamation scheme with Adroit Biomed Limited. The NCLT has ordered this meeting. The cut-off date for voting eligibility is August 10, 2026.
Read the summary - Medium impact
Alkem Labs Acquires 79.36 Crore Shares in Subsidiary Alkem Medtech for ₹1100 Crore
Alkem Laboratories acquired 79.36 crore equity shares in its subsidiary, Alkem Medtech, for ₹1100 crore. The acquisition aims to secure 51-55% stake in Occlutech Holding AG. Alkem Medtech reported ₹15.13 crore turnover for FY26 and operates in the medical device sector.
Read the summary - Medium impact
Alkem Labs to hold Shareholder Meeting on Aug 17 for Amalgamation Scheme
Alkem Laboratories Limited will hold a shareholder meeting on August 17, 2026, via video conference to approve the amalgamation scheme with Adroit Biomed Limited. Remote e-voting is available from August 12 to August 16, 2026. The cut-off date for voting eligibility is August 10, 2026.
Read the summary - Medium impact
Alkem Labs Announces 52nd AGM on Aug 27, Recommends Final Dividend of ₹10
Alkem Laboratories will hold its 52nd AGM on August 27, 2026, via VC/OAVM. The Board recommended a final dividend of ₹10 per equity share for FY26, payable from September 1, 2026, subject to shareholder approval. TDS will be applicable on dividend payments made after April 1, 2026.
Read the summary - Low impact
Alkem Labs Schedules Investor Meeting on July 6th
Alkem Laboratories Limited will conduct an in-person, one-on-one meeting with Sprucegrove Investments on July 6th, 2026, in Mumbai. This meeting is part of the company's ongoing investor relations activities.
Read the summary - Low impact
Alkem Labs to hold virtual investor meeting on July 3, 2026
Alkem Laboratories Limited will conduct a virtual investor meeting with TA Associates on July 3, 2026. The schedule is tentative and subject to change.
Read the summary - Medium impact
Alkem Medtech Executes First Supplementary Agreement for Occlutech Acquisition
Alkem Medtech Private Limited, a subsidiary of Alkem Laboratories, executed a First Supplementary Agreement to a Share Purchase Agreement dated March 6, 2026. This progresses the plan to acquire between 51% and 55% of Swiss company Occlutech Holding AG.
Read the summary - Low impact
Alkem Laboratories: Trading Window Closure from June 29, 2026
Alkem Laboratories Limited will close its trading window from June 29, 2026. The closure is until 48 hours after the announcement of Q1 FY27 financial results. This is as per the company's insider trading code.
Read the summary - Low impact
Alkem Labs Schedules Investor Meeting on June 19, 2026
Alkem Laboratories Limited will hold a virtual meeting with Millennium Management on June 19, 2026. The schedule may change due to exigencies.
Read the summary - Low impact
Alkem Labs Schedules One-on-One Investor Meet on June 16, 2026
Alkem Laboratories Limited will hold a one-on-one in-person meeting with Haitong Securities India Private Limited on June 16, 2026, in Mumbai. The schedule may be subject to change.
Read the summary - Medium impact
Alkem Labs launches first India-made semaglutide pre-filled syringes at ₹350
Alkem Laboratories is the first in India to launch semaglutide in single-shot pre-filled syringes, with prices starting at ₹350. This follows the March 2026 launch of semaglutide injection pens. The new format aims to improve patient access and convenience for managing Type 2 diabetes and obesity.
Read the summary - High impact
Alkem Labs Q4 FY26 Earnings Call Transcript Released
Alkem Labs released its Q4 FY26 earnings call transcript on May 28, 2026. The company achieved a landmark FY26 with EBITDA crossing ₹3,000 crore. Q4 revenue was ₹3,603.3 crore (up 14.6% YoY), with international sales up 25.4%. Key growth drivers include the semaglutide launch and strong performance in India and the U.S. The Occlutech acquisition is nearing completion.
Read the summary - Low impact
Alkem Labs Publishes Q4 FY26 Financial Results in Newspapers
Alkem Laboratories Limited announced its financial results for the quarter and year ended March 31, 2026. The results were published in leading newspapers and are available on the company's website. Manish Narang, President - Legal, Company Secretary & Compliance Officer, provided the disclosure.
Read the summary - Low impact
Alkem Labs Q4FY26 & FY26 Earnings Conference Call Audio Recording Available
Alkem Laboratories Limited has made the audio recording of its Q4FY26 and FY2026 Earnings Conference Call available on its website. This update follows the company's financial disclosures for the respective periods.
Read the summary - Low impact
Alkem Laboratories: Trading Window Reopens June 1st Post Q4 FY26 Results
Alkem Laboratories announced its trading window will reopen on June 1st, 2026. This follows the release of financial results for the quarter and year ended March 31st, 2026, communicated on May 28th, 2026. The window had been closed since March 30th, 2026.
Read the summary - High impact
Alkem Labs Q4FY26 Revenue Up 14.6% to ₹36,033 Million, EBITDA Grows 32.2%
Alkem Laboratories reported record EBITDA for FY26 and strong Q4FY26 results. Q4 revenue grew 14.6% YoY to ₹36,033 million, with EBITDA up 32.2% to ₹5,174 million. FY26 revenue increased 13.5% to ₹147,123 million, and EBITDA grew 19.6% to ₹30,052 million. Domestic sales rose 8.8% in Q4, while international sales saw robust growth, particularly in the US.
Read the summary - Medium impact
Alkem Labs Board Approves FY26 Results, Recommends ₹10 Dividend, Reappoints Director
Alkem Laboratories approved FY26 audited financial results and recommended a final dividend of ₹10 per share. The 52nd AGM is scheduled for August 27, 2026. Mrs. Madhurima Singh was re-appointed as Executive Director for five years from December 20, 2026.
Read the summary - Medium impact
Alkem Labs recommends ₹10 dividend; AGM on Aug 27; Re-appoints Madhurima Singh
Alkem Laboratories approved Q4 FY26 results and recommended a final dividend of ₹10 per share. The 52nd AGM is set for August 27, 2026, with August 7, 2026, as the record date for dividend payment. Mrs. Madhurima Singh was re-appointed as Executive Director for five years from December 20, 2026.
Read the summary - Medium impact
Alkem Labs recommends ₹10 dividend; AGM on Aug 27, 2026
Alkem Laboratories recommended a final dividend of ₹10 per equity share for FY26. The company will hold its 52nd AGM on August 27, 2026, and has fixed August 7, 2026, as the record date for dividend payment. Mrs. Madhurima Singh's re-appointment as Executive Director was also approved.
Read the summary - Low impact
Alkem Laboratories Approves Re-appointment of Mrs. Madhurima Singh as Executive Director
Alkem Laboratories announced the re-appointment of Mrs. Madhurima Singh as an Executive Director. The term is for five years, starting December 20, 2026, and ending December 19, 2031. Shareholder approval is required at the upcoming AGM.
Read the summary - Medium impact
Alkem Labs recommends ₹10 final dividend; AGM on Aug 27
Alkem Laboratories approved its Q4 and FY26 results, recommending a final dividend of ₹10 per share. The company scheduled its AGM for August 27, 2026, and set August 7, 2026, as the record date for dividend payment. Mrs. Madhurima Singh's re-appointment as Executive Director was also approved.
Read the summary - Low impact
Alkem Laboratories: Schedules Analyst/Investor Meet on May 29, 2026
Alkem Laboratories will conduct an in-person, one-on-one meeting with SBI Mutual Fund on May 29, 2026, in Mumbai. The schedule is subject to change.
Read the summary - Low impact
Alkem Labs to Discuss Q4FY26 & FY26 Results on May 28, 2026
Alkem Laboratories will host a conference call on May 28, 2026, at 4:30 PM IST to discuss its Q4FY26 and FY26 financial results. The call will feature MD Sandeep Singh, CEO Dr. Vikas Gupta, and CFO Nitin Agrawal.
Read the summary - Low impact
Alkem Labs Appoints Mr. Chanakya Misra to Senior Management
Alkem Laboratories Limited appointed Mr. Chanakya Misra to a senior management position, effective May 18, 2026. Mr. Misra has over 25 years of experience in pharmaceuticals and healthcare. He holds an MBA and a Bachelor of Pharmacy.
Read the summary - Medium impact
Alkem Laboratories CRO facility in Taloja successfully clears US FDA inspection without 483.
Alkem Laboratories' CRO facility in Taloja, Maharashtra, was inspected by the US FDA on May 8th, 2026. The inspection concluded without any Form 483 observations being issued.
Read the summary - Low impact
Alkem Labs Receives Favorable GST Order, Demand of ₹69.65 Crore Dropped
Alkem Laboratories received a favorable GST order dropping a demand of ₹69.65 crore plus applicable interest and penalty. The order was received on May 4, 2026. The company stated there is no material financial or operational impact.
Read the summary - Low impact
Alkem Labs Receives Income Tax Order; No Material Financial Impact Expected
Alkem Laboratories received an Income Tax order for AY 2023-24, disallowing part of an 80IE deduction and involving transfer pricing adjustments. A tax amount of ₹333.38 crore is disputed, but no payment is due to MAT credit utilization. The company expects no material financial impact and will appeal the order.
Read the summary - Medium impact
Alkem Laboratories Announces CEO Resignation, Dr. Vikas Gupta to Exit June 30, 2026
Dr. Vikas Gupta has resigned as Chief Executive Officer of Alkem Laboratories. He will continue until June 30, 2026, to facilitate a smooth transition. The company has filed the necessary disclosures regarding this change in key managerial personnel.
Read the summary - Medium impact
Alkem Labs Incorporates Wholly Owned Subsidiary in Dubai for Export Expansion
Alkem Laboratories incorporated a wholly-owned subsidiary, Alkem Pharma Trading FZCO, in Dubai, UAE. The subsidiary aims to export Alkem's products to African, South East Asian, and non-UAE markets. It has an authorized and subscribed capital of AED 3,670,000.
Read the summary - Low impact
Alkem Labs Submits Revised XBRL Financial Results for Q4 FY25
Alkem Laboratories Limited has submitted revised XBRL financial results for the quarter ended March 31, 2025. This submission addresses discrepancies noted by the National Stock Exchange of India. Both standalone and consolidated results have been resubmitted.
Read the summary - Low impact
Alkem Laboratories Launches 'A to Z Daily' Multivitamin Supplement
Alkem Laboratories launched 'A to Z Daily', an everyday multivitamin supplement for adults. It contains 26 essential vitamins, minerals, and botanicals like Ashwagandha and Brahmi to support energy, immunity, and cognitive function. The product aims to manage stress and fatigue for holistic well-being.
Read the summary - Low impact
Alkem Labs Promoter Group Declares No Encumbrance in FY26
Alkem Laboratories Limited's promoter group, through Basudeo N. Singh, declared no encumbrance on shares during FY25-26. This aligns with SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Read the summary - Medium impact
Alkem Labs hikes Ujjain plant investment to ₹1,036 crore
Alkem Laboratories has increased its investment for a new manufacturing facility in Ujjain, Madhya Pradesh. The total investment has been revised upwards to ₹1,036 crore from the earlier ₹533 crore. The facility will be set up on approximately 30 acres of land.
Read the summary - Low impact
Alkem Labs Announces Changes in Senior Management
Alkem Laboratories announced the cessation of Mr. Ravinder Chaklam due to superannuation, effective March 24, 2026. Mr. Mukesh Tiwari also ceases to hold a senior management position, effective October 1, 2025, due to an appointment in a subsidiary.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio